Brief: Chinook Therapeutics Presents Bion-1301 Interim Phase 1/2 Data In Patients With Iga Nephropathy (Igan) At The 58Th Era-Edta Virtual Congress

Chinook Therapeutics

08/06/2021 13:28

June 8 (Reuters) - Chinook Therapeutics Inc  KDNY.O :
    * CHINOOK THERAPEUTICS PRESENTS BION-1301 INTERIM PHASE 1/2
DATA
IN PATIENTS WITH IGA NEPHROPATHY (IGAN) AT THE 58TH ERA-EDTA
VIRTUAL CONGRESS
    * CHINOOK THERAPEUTICS - BION-1301 HAS BEEN WELL-TOLERATED
TO DATE
IN PATIENTS WITH IGAN
    * CHINOOK THERAPEUTICS INC - BION-1301 HAS DURABLY REDUCED
GD-IGA1, IGA, IGM, AND TO A LESSER EXTENT, IGG LEVELS IN
PATIENTS WITH IGAN
    * CHINOOK THERAPEUTICS - BION-1301 DEMONSTRATED CLINICALLY
MEANINGFUL MEAN REDUCTION IN 24-HOUR PROTEINURIA IN FIRST
SEVERAL PATIENTS ENROLLED IN STUDY

Source text for Eikon:  ID:nGNX9FLyTD 
Further company coverage:  KDNY.O 

 ((Reuters.Briefs@thomsonreuters.com;))